Analysis of Long-term (Investment) Activity Ratios
Quarterly Data
Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Long-term Activity Ratios (Summary)
DexCom Inc., long-term (investment) activity ratios (quarterly data)
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
| Long-term activity ratio | Description | The company |
|---|---|---|
| Net fixed asset turnover | An activity ratio calculated as total revenue divided by net fixed assets. | DexCom Inc. net fixed asset turnover ratio improved from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023. |
| Net fixed asset turnover (including operating lease, right-of-use asset) | An activity ratio calculated as total revenue divided by net fixed assets (including operating lease, right-of-use asset). | DexCom Inc. net fixed asset turnover ratio (with operating lease, right-of-use asset) improved from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023. |
| Total asset turnover | An activity ratio calculated as total revenue divided by total assets. | DexCom Inc. total asset turnover ratio deteriorated from Q1 2023 to Q2 2023 but then improved from Q2 2023 to Q3 2023 not reaching Q1 2023 level. |
| Equity turnover | An activity ratio calculated as total revenue divided by shareholders’ equity. | DexCom Inc. equity turnover ratio improved from Q1 2023 to Q2 2023 but then slightly deteriorated from Q2 2023 to Q3 2023. |
Net Fixed Asset Turnover
DexCom Inc., net fixed asset turnover calculation (quarterly data)
| Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||
| Revenue | 975,000) | 871,300) | 741,500) | 815,200) | 769,600) | 696,200) | 628,800) | 698,200) | 650,200) | 595,100) | 505,000) | 568,900) | 500,900) | 451,800) | 405,100) | 462,800) | 396,300) | 336,400) | 280,500) | 338,000) | 266,700) | 242,500) | 184,400) | |||||||
| Property and equipment, net | 1,078,900) | 1,077,600) | 1,075,500) | 1,055,600) | 1,002,500) | 942,900) | 856,500) | 801,800) | 742,200) | 676,000) | 589,900) | 515,300) | 461,800) | 384,300) | 346,100) | 321,300) | 301,000) | 253,200) | 221,400) | 183,100) | 169,600) | 156,800) | 152,400) | |||||||
| Long-term Activity Ratio | ||||||||||||||||||||||||||||||
| Net fixed asset turnover1 | 3.15 | 2.97 | 2.81 | 2.76 | 2.79 | 2.84 | 3.00 | 3.05 | 3.12 | 3.21 | 3.44 | 3.74 | 3.94 | 4.47 | 4.62 | 4.59 | 4.49 | 4.82 | 5.09 | 5.63 | — | — | — | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Net Fixed Asset Turnover, Competitors2 | ||||||||||||||||||||||||||||||
| Abbott Laboratories | 4.18 | 4.26 | 4.47 | 4.76 | 5.18 | 5.17 | 5.00 | 4.81 | 4.79 | 4.56 | 4.23 | 3.83 | 3.74 | 3.77 | 4.06 | 3.97 | — | — | — | — | — | — | — | |||||||
| Cigna Group | 48.12 | 47.67 | 47.44 | 47.53 | 47.84 | 48.61 | 47.95 | 46.73 | 41.42 | 40.56 | 39.29 | 37.85 | 37.05 | 36.02 | 35.37 | 34.45 | — | — | — | — | — | — | — | |||||||
| CVS Health Corp. | 26.62 | 26.00 | 25.63 | 24.98 | 24.90 | 24.05 | 23.26 | 22.56 | 22.24 | 21.90 | 21.42 | 21.25 | 21.48 | 21.52 | 21.49 | 21.24 | — | — | — | — | — | — | — | |||||||
| Elevance Health Inc. | 39.41 | 36.19 | 36.14 | 36.07 | 36.22 | 36.17 | 35.81 | 34.94 | 34.54 | 34.17 | 34.94 | 34.69 | 34.61 | 32.74 | 32.30 | 32.92 | — | — | — | — | — | — | — | |||||||
| Humana Inc. | 30.35 | 29.59 | 29.40 | 28.71 | 28.37 | 28.64 | 27.05 | 26.97 | 27.83 | 29.47 | 31.04 | 32.05 | 32.90 | 33.07 | 33.20 | 32.93 | — | — | — | — | — | — | — | |||||||
| Intuitive Surgical Inc. | 2.23 | 2.35 | 2.49 | 2.62 | 2.73 | 2.83 | 3.00 | 3.04 | 3.16 | 3.13 | 2.86 | 2.76 | 2.85 | 3.00 | 3.36 | 3.52 | — | — | — | — | — | — | — | |||||||
| Medtronic PLC | 5.66 | 5.82 | 5.88 | 5.85 | 6.05 | 6.13 | 6.12 | 5.77 | 5.56 | 5.64 | 5.72 | 5.99 | 6.52 | 6.50 | 6.51 | 6.54 | — | — | — | — | — | — | — | |||||||
| UnitedHealth Group Inc. | 32.18 | 31.60 | 31.35 | 31.81 | 33.07 | 32.33 | 32.16 | 31.81 | 31.77 | 30.94 | 30.76 | 29.64 | 30.80 | 30.30 | 29.91 | 27.60 | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2023 Calculation
Net fixed asset turnover
= (RevenueQ3 2023
+ RevenueQ2 2023
+ RevenueQ1 2023
+ RevenueQ4 2022)
÷ Property and equipment, net
= (975,000 + 871,300 + 741,500 + 815,200)
÷ 1,078,900 = 3.15
2 Click competitor name to see calculations.
| Long-term activity ratio | Description | The company |
|---|---|---|
| Net fixed asset turnover | An activity ratio calculated as total revenue divided by net fixed assets. | DexCom Inc. net fixed asset turnover ratio improved from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023. |
Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset)
DexCom Inc., net fixed asset turnover (including operating lease, right-of-use asset) calculation (quarterly data)
| Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||
| Revenue | 975,000) | 871,300) | 741,500) | 815,200) | 769,600) | 696,200) | 628,800) | 698,200) | 650,200) | 595,100) | 505,000) | 568,900) | 500,900) | 451,800) | 405,100) | 462,800) | 396,300) | 336,400) | 280,500) | 338,000) | 266,700) | 242,500) | 184,400) | |||||||
| Property and equipment, net | 1,078,900) | 1,077,600) | 1,075,500) | 1,055,600) | 1,002,500) | 942,900) | 856,500) | 801,800) | 742,200) | 676,000) | 589,900) | 515,300) | 461,800) | 384,300) | 346,100) | 321,300) | 301,000) | 253,200) | 221,400) | 183,100) | 169,600) | 156,800) | 152,400) | |||||||
| Operating lease right-of-use assets | 73,400) | 76,300) | 78,000) | 80,000) | 73,100) | 77,900) | 82,300) | 88,100) | 91,300) | 94,800) | 98,800) | 93,300) | 94,300) | 71,600) | 73,800) | 71,500) | 34,600) | 35,800) | 27,700) | —) | —) | —) | —) | |||||||
| Property and equipment, net (including operating lease, right-of-use asset) | 1,152,300) | 1,153,900) | 1,153,500) | 1,135,600) | 1,075,600) | 1,020,800) | 938,800) | 889,900) | 833,500) | 770,800) | 688,700) | 608,600) | 556,100) | 455,900) | 419,900) | 392,800) | 335,600) | 289,000) | 249,100) | 183,100) | 169,600) | 156,800) | 152,400) | |||||||
| Long-term Activity Ratio | ||||||||||||||||||||||||||||||
| Net fixed asset turnover (including operating lease, right-of-use asset)1 | 2.95 | 2.77 | 2.62 | 2.56 | 2.60 | 2.62 | 2.74 | 2.75 | 2.78 | 2.82 | 2.94 | 3.17 | 3.27 | 3.76 | 3.81 | 3.76 | 4.03 | 4.23 | 4.53 | 5.63 | — | — | — | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset), Competitors2 | ||||||||||||||||||||||||||||||
| CVS Health Corp. | 11.33 | 11.01 | 10.81 | 10.46 | 10.17 | 9.80 | 9.44 | 9.09 | 8.55 | 8.37 | 8.15 | 8.04 | 8.08 | 8.02 | 7.95 | 7.77 | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2023 Calculation
Net fixed asset turnover (including operating lease, right-of-use asset)
= (RevenueQ3 2023
+ RevenueQ2 2023
+ RevenueQ1 2023
+ RevenueQ4 2022)
÷ Property and equipment, net (including operating lease, right-of-use asset)
= (975,000 + 871,300 + 741,500 + 815,200)
÷ 1,152,300 = 2.95
2 Click competitor name to see calculations.
| Long-term activity ratio | Description | The company |
|---|---|---|
| Net fixed asset turnover (including operating lease, right-of-use asset) | An activity ratio calculated as total revenue divided by net fixed assets (including operating lease, right-of-use asset). | DexCom Inc. net fixed asset turnover ratio (with operating lease, right-of-use asset) improved from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023. |
Total Asset Turnover
DexCom Inc., total asset turnover calculation (quarterly data)
| Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||
| Revenue | 975,000) | 871,300) | 741,500) | 815,200) | 769,600) | 696,200) | 628,800) | 698,200) | 650,200) | 595,100) | 505,000) | 568,900) | 500,900) | 451,800) | 405,100) | 462,800) | 396,300) | 336,400) | 280,500) | 338,000) | 266,700) | 242,500) | 184,400) | |||||||
| Total assets | 6,596,200) | 6,820,700) | 5,515,900) | 5,391,700) | 4,899,200) | 5,217,400) | 5,057,000) | 4,863,600) | 4,775,900) | 4,503,800) | 4,389,800) | 4,290,500) | 3,833,200) | 3,521,800) | 2,447,900) | 2,395,000) | 2,185,700) | 2,065,900) | 1,974,000) | 1,916,000) | 1,114,300) | 1,007,500) | 896,800) | |||||||
| Long-term Activity Ratio | ||||||||||||||||||||||||||||||
| Total asset turnover1 | 0.52 | 0.47 | 0.55 | 0.54 | 0.57 | 0.51 | 0.51 | 0.50 | 0.49 | 0.48 | 0.46 | 0.45 | 0.47 | 0.49 | 0.65 | 0.62 | 0.62 | 0.59 | 0.57 | 0.54 | — | — | — | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Total Asset Turnover, Competitors2 | ||||||||||||||||||||||||||||||
| Abbott Laboratories | 0.55 | 0.55 | 0.56 | 0.59 | 0.62 | 0.61 | 0.60 | 0.57 | 0.57 | 0.55 | 0.51 | 0.48 | 0.47 | 0.46 | 0.48 | 0.47 | — | — | — | — | — | — | — | |||||||
| Cigna Group | 1.26 | 1.23 | 1.23 | 1.25 | 1.24 | 1.17 | 1.15 | 1.11 | 1.09 | 1.07 | 1.06 | 1.02 | 0.97 | 0.96 | 0.99 | 0.98 | — | — | — | — | — | — | — | |||||||
| CVS Health Corp. | 1.38 | 1.35 | 1.38 | 1.41 | 1.36 | 1.33 | 1.28 | 1.25 | 1.21 | 1.20 | 1.18 | 1.16 | 1.14 | 1.12 | 1.13 | 1.15 | — | — | — | — | — | — | — | |||||||
| Elevance Health Inc. | 1.52 | 1.51 | 1.46 | 1.51 | 1.48 | 1.47 | 1.42 | 1.41 | 1.35 | 1.33 | 1.29 | 1.39 | 1.34 | 1.28 | 1.31 | 1.33 | — | — | — | — | — | — | — | |||||||
| Humana Inc. | 1.81 | 1.73 | 1.74 | 2.15 | 1.80 | 1.91 | 1.86 | 1.87 | 1.78 | 2.08 | 2.08 | 2.17 | 1.90 | 1.82 | 1.94 | 2.21 | — | — | — | — | — | — | — | |||||||
| Intuitive Surgical Inc. | 0.47 | 0.48 | 0.49 | 0.48 | 0.46 | 0.44 | 0.43 | 0.42 | 0.42 | 0.42 | 0.39 | 0.39 | 0.41 | 0.43 | 0.47 | 0.46 | — | — | — | — | — | — | — | |||||||
| Medtronic PLC | 0.33 | 0.33 | 0.35 | 0.35 | 0.35 | 0.35 | 0.34 | 0.32 | 0.29 | 0.29 | 0.30 | 0.32 | 0.33 | 0.34 | 0.34 | 0.34 | — | — | — | — | — | — | — | |||||||
| UnitedHealth Group Inc. | 1.26 | 1.23 | 1.18 | 1.31 | 1.29 | 1.32 | 1.33 | 1.34 | 1.30 | 1.29 | 1.27 | 1.30 | 1.31 | 1.28 | 1.29 | 1.38 | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2023 Calculation
Total asset turnover
= (RevenueQ3 2023
+ RevenueQ2 2023
+ RevenueQ1 2023
+ RevenueQ4 2022)
÷ Total assets
= (975,000 + 871,300 + 741,500 + 815,200)
÷ 6,596,200 = 0.52
2 Click competitor name to see calculations.
| Long-term activity ratio | Description | The company |
|---|---|---|
| Total asset turnover | An activity ratio calculated as total revenue divided by total assets. | DexCom Inc. total asset turnover ratio deteriorated from Q1 2023 to Q2 2023 but then improved from Q2 2023 to Q3 2023 not reaching Q1 2023 level. |
Equity Turnover
DexCom Inc., equity turnover calculation (quarterly data)
| Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||
| Revenue | 975,000) | 871,300) | 741,500) | 815,200) | 769,600) | 696,200) | 628,800) | 698,200) | 650,200) | 595,100) | 505,000) | 568,900) | 500,900) | 451,800) | 405,100) | 462,800) | 396,300) | 336,400) | 280,500) | 338,000) | 266,700) | 242,500) | 184,400) | |||||||
| Stockholders’ equity | 2,267,900) | 2,100,400) | 2,233,000) | 2,131,800) | 1,824,500) | 2,255,900) | 2,189,300) | 2,251,500) | 2,136,100) | 1,997,600) | 1,903,200) | 1,826,500) | 1,499,300) | 1,353,900) | 934,500) | 882,600) | 764,300) | 688,300) | 668,600) | 663,300) | 562,200) | 482,100) | 421,700) | |||||||
| Long-term Activity Ratio | ||||||||||||||||||||||||||||||
| Equity turnover1 | 1.50 | 1.52 | 1.35 | 1.36 | 1.53 | 1.19 | 1.17 | 1.09 | 1.09 | 1.09 | 1.06 | 1.05 | 1.21 | 1.27 | 1.71 | 1.67 | 1.77 | 1.77 | 1.69 | 1.56 | — | — | — | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Equity Turnover, Competitors2 | ||||||||||||||||||||||||||||||
| Abbott Laboratories | 1.07 | 1.08 | 1.12 | 1.19 | 1.26 | 1.25 | 1.26 | 1.20 | 1.23 | 1.19 | 1.11 | 1.06 | 1.03 | 1.03 | 1.06 | 1.03 | — | — | — | — | — | — | — | |||||||
| Cigna Group | 4.13 | 4.07 | 4.09 | 4.00 | 3.98 | 3.88 | 3.81 | 3.66 | 3.56 | 3.40 | 3.36 | 3.16 | 3.24 | 3.24 | 3.39 | 3.36 | — | — | — | — | — | — | — | |||||||
| CVS Health Corp. | 4.66 | 4.65 | 4.62 | 4.53 | 4.45 | 4.08 | 4.05 | 3.87 | 3.82 | 3.79 | 3.81 | 3.86 | 3.86 | 3.87 | 4.01 | 4.00 | — | — | — | — | — | — | — | |||||||
| Elevance Health Inc. | 4.36 | 4.31 | 4.27 | 4.29 | 4.22 | 4.13 | 3.97 | 3.80 | 3.71 | 3.65 | 3.65 | 3.64 | 3.43 | 3.26 | 3.41 | 3.25 | — | — | — | — | — | — | — | |||||||
| Humana Inc. | 5.98 | 5.82 | 5.74 | 6.04 | 5.62 | 5.77 | 5.63 | 5.15 | 4.96 | 5.34 | 5.48 | 5.54 | 4.65 | 4.86 | 5.44 | 5.35 | — | — | — | — | — | — | — | |||||||
| Intuitive Surgical Inc. | 0.55 | 0.56 | 0.57 | 0.56 | 0.53 | 0.50 | 0.49 | 0.48 | 0.48 | 0.48 | 0.45 | 0.45 | 0.47 | 0.50 | 0.54 | 0.54 | — | — | — | — | — | — | — | |||||||
| Medtronic PLC | 0.60 | 0.59 | 0.59 | 0.60 | 0.60 | 0.61 | 0.61 | 0.59 | 0.55 | 0.56 | 0.56 | 0.57 | 0.60 | 0.61 | 0.61 | 0.61 | — | — | — | — | — | — | — | |||||||
| UnitedHealth Group Inc. | 4.22 | 4.19 | 4.10 | 4.14 | 4.19 | 4.18 | 4.06 | 3.98 | 3.95 | 3.92 | 3.94 | 3.90 | 3.85 | 3.87 | 4.29 | 4.17 | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2023 Calculation
Equity turnover
= (RevenueQ3 2023
+ RevenueQ2 2023
+ RevenueQ1 2023
+ RevenueQ4 2022)
÷ Stockholders’ equity
= (975,000 + 871,300 + 741,500 + 815,200)
÷ 2,267,900 = 1.50
2 Click competitor name to see calculations.
| Long-term activity ratio | Description | The company |
|---|---|---|
| Equity turnover | An activity ratio calculated as total revenue divided by shareholders’ equity. | DexCom Inc. equity turnover ratio improved from Q1 2023 to Q2 2023 but then slightly deteriorated from Q2 2023 to Q3 2023. |